Genetic deletion of cell division autoantigen 1 retards diabetes-associated renal injury.
暂无分享,去创建一个
Merlin C. Thomas | M. Cooper | Jiaze Li | Y. Tu | Tieqiao Wu | Aozhi Dai | Yu Wang | Z. Chai | Frank Koentgen | L. Hale | M. Thomas | Lorna J. Hale | M. Cooper | Yugang Tu
[1] R. Grimley,et al. Identification of Novel Interacting Partners of Sirtuin6 , 2012, PloS one.
[2] K. Kuwano,et al. Accelerated epithelial cell senescence in IPF and the inhibitory role of SIRT6 in TGF-β-induced senescence of human bronchial epithelial cells. , 2011, American journal of physiology. Lung cellular and molecular physiology.
[3] M. Cooper,et al. Cell division autoantigen 1 enhances signaling and the profibrotic effects of transforming growth factor-β in diabetic nephropathy. , 2011, Kidney international.
[4] M. Cooper,et al. Cell division autoantigen 1 plays a profibrotic role by modulating downstream signalling of TGF-β in a murine diabetic model of atherosclerosis , 2009, Diabetologia.
[5] Merlin C. Thomas,et al. Receptor for Advanced Glycation End Products (RAGE) Deficiency Attenuates the Development of Atherosclerosis in Diabetes , 2008, Diabetes.
[6] M. V. Dinther,et al. Oral administration of GW788388, an inhibitor of TGF-beta type I and II receptor kinases, decreases renal fibrosis. , 2008, Kidney international.
[7] M. Kretzler,et al. From Fibrosis to Sclerosis Mechanisms of Glomerulosclerosis in Diabetic , 2008 .
[8] N. Laping,et al. Interference with TGF-beta signaling by Smad3-knockout in mice limits diabetic glomerulosclerosis without affecting albuminuria. , 2007, American journal of physiology. Renal physiology.
[9] R. Foley,et al. End-stage renal disease in the United States: an update from the United States Renal Data System. , 2007, Journal of the American Society of Nephrology : JASN.
[10] M. Zhang,et al. ERK, p38, and Smad signaling pathways differentially regulate transforming growth factor-beta1 autoinduction in proximal tubular epithelial cells. , 2006, The American journal of pathology.
[11] Merlin C. Thomas,et al. Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease. , 2006, Journal of the American Society of Nephrology : JASN.
[12] J. Egido,et al. Angiotensin II Activates the Smad Pathway in Vascular Smooth Muscle Cells by a Transforming Growth Factor-β–Independent Mechanism , 2005, Circulation.
[13] M. Cooper,et al. Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. , 2005, Journal of the American Society of Nephrology : JASN.
[14] Merlin C. Thomas,et al. Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products. , 2004, Journal of the American Society of Nephrology : JASN.
[15] E. Bottinger,et al. Utility of endogenous creatinine clearance as a measure of renal function in mice. , 2004, Kidney international.
[16] L. Truong,et al. Advanced glycation end products activate Smad signaling via TGF‐β‐dependent and ‐independent mechanisms: implications for diabetic renal and vascular disease , 2004 .
[17] R. Atkins,et al. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. , 2004, Kidney international.
[18] L. Truong,et al. Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease. , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[19] F. Ziyadeh,et al. Diabetic nephropathy and transforming growth factor-beta: transforming our view of glomerulosclerosis and fibrosis build-up. , 2003, Seminars in nephrology.
[20] J. Egido,et al. Connective Tissue Growth Factor Is a Mediator of Angiotensin II–Induced Fibrosis , 2003, Circulation.
[21] Hong-Jian Zhu,et al. Role of TGF-beta signaling in extracellular matrix production under high glucose conditions. , 2003, Kidney international.
[22] N. Wahab,et al. J Am Soc Nephrol 14: 1358–1373, 2003 Extracellular Matrix Metabolism in Diabetic Nephropathy , 2022 .
[23] C. Tsalamandris,et al. Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. , 2002, Diabetes care.
[24] R. Atkins,et al. Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). , 2001, The Journal of clinical investigation.
[25] A. Mawson,et al. SET-related Cell Division Autoantigen-1 (CDA1) Arrests Cell Growth* , 2001, The Journal of Biological Chemistry.
[26] M. Goumans,et al. Abnormal angiogenesis but intact hematopoietic potential in TGF‐β type I receptor‐deficient mice , 2001, The EMBO journal.
[27] K. Sharma,et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[28] F. Locatelli,et al. End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[29] M. Cooper,et al. A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat (TGR). , 1998, Kidney international.
[30] A. Kulkarni,et al. Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice. , 1995, Development.
[31] A. Kulkarni,et al. Immune dysregulation in TGF-beta 1-deficient mice. , 1994, Journal of immunology.
[32] A. Kulkarni,et al. Transforming growth factor-beta 1 knockout mice. A mutation in one cytokine gene causes a dramatic inflammatory disease. , 1993, The American journal of pathology.
[33] E Ruoslahti,et al. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[34] M. Sporn,et al. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[35] G. Proetzel,et al. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease , 1992, Nature.